Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years.

• Tác giả: Guangfu Cai, Yue Cai, Longqing Cheng, Pan Chi, Long Cui, Yanhong Deng, Jinbo Gao, Meijin Huang, Yan Huang, Zhongcheng Huang, Zonghai Huang, Liang Kang, Ping Lan, Wanglin Li, Junsheng Peng, Donglin Ren, Lishuo Shi, Jianping Wang, Hongbo Wei, Yisheng Wei, Xiaojian Wu, Hao Zhang, Jianwei Zhang, Ren Zhao, Jian Zheng, Hongfeng Zhou, Zhiyang Zhou
• Ngôn ngữ: eng
• Ký hiệu phân loại: 363.34987 Other aspects of public safety
• Thông tin xuất bản: United States : Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2025
• Bộ sưu tập: NCBI
• ID: 61272

Tóm tắt

We present 10-year results of the phase Ⅲ FOWARC trial, which evaluated the efficacy of modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) with or without radiation compared with fluorouracil with radiation in patients with locally advanced rectal cancer. A total of 495 patients age 18-75 years with stage Ⅱ-Ⅲ rectal cancer were randomly assigned to three treatment arms: fluorouracil plus radiotherapy, mFOLFOX6 plus radiotherapy, or mFOLFOX6 alone, followed by surgery and adjuvant chemotherapy. With a median follow-up of 10 years, the 10-year disease-free survival (DFS) rates were 52.5%, 62.6%, and 60.5%, respectively (